ORIGINAL ARTICLE

Ethnic differences in the association of QRS duration with ejection fraction and outcome in heart failure

Crystel M Gijsberts,1,2 Lina Benson,3 Ulf Dahlström,4,5 David Sim,6 Daniel P S Yeo,7 Hean Yee Ong,8 Fazlur Jaufeerally,9,10 Gerard K T Leong,11 Lieng H Ling,12,13 A Mark Richards,12,13,14 Dominique P V de Kleijn,1,2,12,14 Lars H Lund,16,17 Carolyn S P Lam6,10,12,14

ABSTRACT

Background QRS duration (QRSd) criteria for device therapy in heart failure (HF) were derived from predominantly white populations and ethnic differences are poorly understood.

Methods We compared the association of QRSd with ejection fraction (EF) and outcomes between 839 Singaporean Asian and 11 221 Swedish white patients with HF having preserved EF (HFPEF) and HF having reduced EF (HFREF) were followed in prospective population-based HF studies.

Results Compared with whites, Asian patients with HF were younger (62 vs 74 years, p<0.001), had smaller body size (height 163 vs 171 cm, weight 70 vs 80 kg, both p<0.001) and had more severely impaired EF (EF was <30% in 47% of Asians vs 28% of whites). Overall, unadjusted QRSd was shorter in Asians than whites (101 vs 104 ms, p<0.001). Lower EF was associated with longer QRSd (p<0.001), with a steeper association among Asians than whites (pinteraction<0.001), independent of age, sex and clinical covariates (including body size). Excluding patients with left bundle branch block (LBBB) and adjusting for clinical covariates, QRSd was similar in Asians and whites with HFPEF, but longer in Asians compared with whites with HFREF (p=0.001). Longer QRSd was associated with increased risk of HF hospitalisation or death (absolute 2-year event rate for ≤120 ms was 40% and for >120 ms it was 52%; HR for 10 ms increase of QRSd was 1.04 (1.03 to 1.06), p<0.001), independent of age, sex and clinical covariates, with no interaction by ethnicity.

Conclusion We found ethnic differences in the association between EF and QRSd among patients with HF. QRS prolongation was similarly associated with increased risk, but the implications for ethnicity-specific QRSd cut-offs in clinical decision-making require further study.

INTRODUCTION

QRS prolongation (QRS duration (QRSd) ≥120 ms) is an ECG characteristic of left ventricular (LV) remodelling occurring in 14%–47% of patients with heart failure (HF). It is related to reduction in LV ejection fraction (EF) and poor prognosis in HF. QRSd cut-offs are used to guide device therapy decisions in HF with reduced EF (HFREF). However, the vast majority of prior data on QRSd in HF has been derived from studies in white patient populations. Ethnic differences in ECG characteristics, and specifically in QRSd, have been described among adults without HF. However in patients with HF, it is unclear if ethnic differences in QRSd exist or whether the relationships of QRSd with EF and prognosis are modified by ethnicity.

We sought to compare QRSd and its association with EF and prognosis between Asian and white patients with HF from population-based HF cohorts in Singapore and Sweden, respectively. Given that general-population Asian adults have a narrower QRS complex compared with general-population white adults (possibly related to smaller heart sizes in Asians), we hypothesised that among patients with HF, Asians would also have narrower QRS complexes for a given EF. We further hypothesised that there may be important differences in the prognostic impact of QRS prolongation between Asian and white patients with HF.

METHODS

Study population

Our study population consisted of patients with HF from two contemporary population-based observational HF studies recruiting patients with HF regardless of EF, from either in-hospital (hospitalisation with primary diagnosis of HF) or outpatient (visit related to HF management) settings: Asian patients in the Singapore Heart Failure Outcomes and Phenotypes (SHOP) cohort and white patients in the Swedish Heart Failure Registry (SwedeHF). The SHOP study enrolled patients with HF from all public institutions across the nation of Singapore and included a total of 1084 patients enrolled between June 2010 and July 2014. The SHOP protocol has been previously described in detail. Similarly, the SwedeHF study enrolled patients with HF across the nation of Sweden, beginning in 2000. For the current analysis, we applied the same enrolment time frame to the SwedeHF cohort as in the SHOP cohort and thus only included 20 073 patients from SwedeHF who were enrolled from 2010 (excluding the first 30 987 patients enrolled from 2000 to 2009).

We excluded patients with missing EF (70 Asians and 3215 whites), missing QRSd (n=6 Asians and n=4918 whites), missing or inconsistent information on left bundle branch block (LBBB) (n=49 Asians and n=519 whites), device therapy (n=73 Asians and n=0 whites) (already included due to...
missing QRS, which was not registered in case of device therapy)) or who died during hospitalisation or with missing
follow-up information (n=62 Asians and n=200 whites), thereby leaving 839 Asian and 11 221 white patients in the final
study population.

Ethics statement
This study conforms to the Declaration of Helsinki. All SHOP participants provided written informed consent. For the
SwedeHF registry, individual patient consent was not required, but patients were informed of entry into the national registry
and allowed to opt out. Both cohorts were approved by the responsible ethics committees as described earlier for both cohorts.6,9
This study is performed and reported in accordance with the STROBE guidelines for observational research.11

Ethnicity
For SwedeHF, ethnicity on individual basis was not available; all Swedish patients were considered to be of white ethnic back-
ground. In the SHOP cohort, ethnicity was known at the individual level (from Singapore national ID registration): 63% was
of Chinese ethnic background, 27% Malaysian, 9% Indian and 1% of other ethnic background. All SHOP participants were
considered to be of Asian ethnicity for the purpose of this study.

HFREF and HFPEF
In both cohorts, HFREF was defined as clinical features of HF with an ECG EF <50%, as used in most previous studies.12 The
EF of patients with HFREF was further categorised into 40%–
49%, 30%–39% and <30%. HF with preserved EF (HFPEF) was
deefined as clinical features of HF and an ECG EF ≥50%.

Patient characteristics
Baseline patient characteristics were gathered from SwedeHF
and the Swedish Patient Registry for the Swedish cohort. For
SHOP baseline characteristics were collected through a case
record form specifically designed for the cohort (as described earlier).6,8
In SHOP, QRSd was available from automatic ECG readings
and confirmed by independent manual measurement by blinded
trained staff. In SwedeHF, the QRSd was determined by the
reporting clinician and not further specified whether measured
manually or digitally.

For both cohorts, a history of coronary artery disease (CAD)
was defined as either a history of stable CAD (as assessed by a
physician), myocardial infarction, percutaneous coronary inter-
vention (PCI) or coronary artery bypass surgery.

Outcomes
Outcomes were collected through standardised protocols in
both cohorts. Mortality was obtained by checking the national
death registry of Singapore and the Population Registry in
Sweden. HF hospitalisations were obtained from hospital
records in Singapore and ICD-10 code registrations in the main
(first) position of the Patient Registry in Sweden. Follow-up
events were considered after dismissal from the index event.

Statistical analysis
Baseline characteristics were stratified by ethnicity. Continuous,
normally distributed data were presented as means±SD and com-
pared using a t-test. Non-normally distributed data were pre-
sented as medians with IQRs and compared using Kruskal-Wallis
testing. Categorical data were reported as percentages and com-
pared using χ² testing.

Because of covariates that were potentially missing not-comple-
tely-at-random, covariates were imputed for multivariable analysis
by means of single imputation with 10 iterations using all covar-
iates in the two cohorts separately, using the ‘MICE’ package
for R.13 Primary variables of interest and outcome measures were
not imputed (EF, QRSd and events during follow-up).

We compared QRSd between the Asians and whites by EF
strata (HFREF or HFPEF) using linear regression. Due to the
non-normal distribution of residuals of QRSd in the linear
regression model, it was analysed as 1/QRSd. The transforma-
tion method was determined by means of the Box-Cox trans-
formation.14 We examined whether ethnicity modified the
association between EF and 1/QRSd using interaction terms in a
multivariable model.

Next, we determined how ethnicity affected 1/QRS separately
in patients with HFPEF and patients with HFREF with and
without LBBB in models adjusted for age, sex, EF (only for
HFREF), height, body mass index (BMI), diastolic blood pres-
sure, hypertension, diabetes, smoking, history of CAD, PCI,
coronary artery bypass grafting, valve surgery, atrial fibrillation
or flutter (AF), stroke, peripheral arterial disease or chronic
obstructive pulmonary disease (COPD), New York Heart
Association (NYHA) class, N-terminal pro-brain natriuretic peptide
(NTproBNP), creatinine clearance (calculated with Cockcroft-
Gault formula), haemoglobin, duration of HF (>6 vs ≤6 months),
heart rate, medications (β blocker, ACE inhibitor, angiotensin
II receptor blocker, diuretic, statin, antiplatelet therapy) and LBBB
(only for analyses including patients with LBBB). These covariates
were pre-specified based on clinical relevance.

Subsequently, we assessed the effect of cumulatively adding
each covariate to the model containing the primary variable
(ethnicity). Ethnicity-specific back-transformed fitted values of
1/QRSd were calculated for all subgroups of patients from the
multivariable models.

Finally, we examined the ethnicity-specific association of
QRSd (which had a linear relation with outcome and thus
required no transformation) with a composite end point of HF
hospitalisation and all-cause mortality in Cox regression models
for HFPEF and HFREF separately. The association of QRSd
with outcome was tested in a univariable model (including inter-
action analysis) and in a model including all covariates as men-
tioned above. The additional analysis for outcome HF was
censored at death. The HRs of QRSd (reference value 120) for
Asians and whites were visualised using the coxsimLinear and
simGG functions from the ‘simPH’13 package for R.

All analyses were performed using Rstudio (J Allaire. RStudio:
integrated development environment for R. Boston, Massachusetts,
USA, 2012.) and R software (R Core Team. R: A Language and
Environment for Statistical Computing, 2013.) for statistical
computing (V3.1.2). A p value of <0.05 was considered to be
statistically significant and all p values were two-sided.

RESULTS
Baseline characteristics by ethnicity
Compared with white patients with HF, Asian patients with HF
were younger (62 vs 74 years, p<0.001), had smaller body size
(height 163 vs 171 cm, weight 70 vs 80 kg and BMI 26.3 vs
27.1, all p<0.001) and had more severely impaired EF (EF was
<30% in 47% of Asians vs 28% of whites) but less severe
NYHA classification and lower NTproBNP levels (median 2044
pg/mL, p<0.001) (table 1). A history of CAD was more common
among Asians (53% vs 45%, p<0.001), but AF and
valve surgery were more common among whites (50% vs 23%
and 5% vs 1% respectively; both p<0.001) (table 1).


Heart failure and cardiomyopathies
QRSd in Asians and whites with HFPEF and HFREF

The distribution of QRSd between Asians and whites is depicted in figure 1. The overall relationship of QRSd with EF differed by ethnicity: in Asians, a reduction in EF was related to a steeper increase of QRSd compared with whites (pinteraction <0.001 in the multivariable model). Similar results were obtained when LBBB was excluded.

As described in our methods section, QRSd was analysed as 1/QRSd due to non-normally distributed residuals in the regression analysis. In the total population, QRSd was shorter in Asians than whites in univariable analysis (back-transformed values from 1/QRS: 101 vs 104 ms, p<0.001), both in HFPEF (91 vs 96 ms, p<0.001) and HFREF (104 vs 106 ms, p=0.012). LBBB was more common in white compared with Asian patients (16 vs 23%).

**Table 1** Baseline characteristics of patients with HF stratified by ethnicity

<table>
<thead>
<tr>
<th></th>
<th>Asian</th>
<th>Percentage missing</th>
<th>White</th>
<th>Percentage missing</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>839</td>
<td>0</td>
<td>11,221</td>
<td>0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Age (years, mean±SD)</td>
<td>61.8±12.2</td>
<td>0</td>
<td>73.5±12.3</td>
<td>0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Sex (female %)</td>
<td>24.2</td>
<td>0</td>
<td>38.4</td>
<td>0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Height (cm, mean±SD)</td>
<td>162.5±8.6</td>
<td>1.5</td>
<td>171.3±9.9</td>
<td>48.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Weight (kg, mean±SD)</td>
<td>69.6±15.8</td>
<td>1.4</td>
<td>79.5±18.7</td>
<td>7.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>BMI (kg/m², mean±SD)</td>
<td>26.3±5.4</td>
<td>1.9</td>
<td>27.1±5.6</td>
<td>49.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>SBP (mm Hg, mean±SD)</td>
<td>125.9±22.5</td>
<td>0.2</td>
<td>128.2±21.2</td>
<td>1.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>DBP (mm Hg, mean±SD)</td>
<td>71.9±13.0</td>
<td>0.2</td>
<td>73.6±12.4</td>
<td>1.2</td>
<td>0.003</td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td>72.6</td>
<td>1.2</td>
<td>54.9</td>
<td>1.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Diabetes (%)</td>
<td>55.7</td>
<td>0.2</td>
<td>23.7</td>
<td>0.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Smoking (%)</td>
<td>46.6</td>
<td>0.2</td>
<td>43.0</td>
<td>0.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Non-smoker</td>
<td>46.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ex-smoker</td>
<td>29.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current smoker</td>
<td>23.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatinine clearance* (mL/min, mean±SD)</td>
<td>66.3±38.8</td>
<td>4.4</td>
<td>68.3±33.7</td>
<td>7.8</td>
<td>0.117</td>
</tr>
</tbody>
</table>

**Medical history**

<table>
<thead>
<tr>
<th></th>
<th>Asian</th>
<th>Percentage missing</th>
<th>White</th>
<th>Percentage missing</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAD (%)</td>
<td>53.4</td>
<td>4.3</td>
<td>45.0</td>
<td>0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>PCI (%)</td>
<td>19.9</td>
<td>1.5</td>
<td>16.6</td>
<td>0</td>
<td>0.018</td>
</tr>
<tr>
<td>CABG (%)</td>
<td>13.7</td>
<td>0.6</td>
<td>22.4</td>
<td>0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Valve surgery (%)</td>
<td>0.7</td>
<td>0.6</td>
<td>5.2</td>
<td>0.6</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Atrial fibrillation/flutter (%)</td>
<td>23.3</td>
<td>0.8</td>
<td>50.0</td>
<td>0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Stroke (%)</td>
<td>10.3</td>
<td>0.2</td>
<td>17.2</td>
<td>0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>PAD (%)</td>
<td>4.2</td>
<td>0.8</td>
<td>10.4</td>
<td>0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>COPD (%)</td>
<td>8.3</td>
<td>0.5</td>
<td>18.6</td>
<td>0</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

**Heart failure characteristics**

<table>
<thead>
<tr>
<th></th>
<th>Asian</th>
<th>Percentage missing</th>
<th>White</th>
<th>Percentage missing</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration of HF &gt;6 months (%)</td>
<td>40.2</td>
<td>0.7</td>
<td>39.3</td>
<td>1.1</td>
<td>0.613</td>
</tr>
<tr>
<td>EF (%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>=&gt;50</td>
<td>22.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>40–49</td>
<td>11.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30–39</td>
<td>19.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;30</td>
<td>47.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NYHA (%)</td>
<td>1.3</td>
<td>1.3</td>
<td>35.1</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>26.9</td>
<td></td>
<td>11.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>58.1</td>
<td></td>
<td>49.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>14.0</td>
<td></td>
<td>35.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>1.0</td>
<td></td>
<td>3.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart rate (bpm, mean±SD)</td>
<td>75.4±14.3</td>
<td>0</td>
<td>74.5±15.9</td>
<td>2.1</td>
<td>0.124</td>
</tr>
<tr>
<td>LBBB (%)</td>
<td>4.6</td>
<td>0</td>
<td>16.0</td>
<td>0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>NTproBNP (pg/mL, median (IQR))</td>
<td>2044 (808, 4266)</td>
<td>0</td>
<td>2700 (1178, 5858)</td>
<td>57.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Haemoglobin (g/L, mean±SD)</td>
<td>13.0±2.1</td>
<td>0</td>
<td>13.2±1.8</td>
<td>0</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

**Medication use**

<table>
<thead>
<tr>
<th></th>
<th>Asian</th>
<th>Percentage missing</th>
<th>White</th>
<th>Percentage missing</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-blocker (%)</td>
<td>93.6</td>
<td>0</td>
<td>87.4</td>
<td>0.4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ACE inhibitor (%)</td>
<td>66.0</td>
<td>0</td>
<td>65.2</td>
<td>0.4</td>
<td>0.656</td>
</tr>
<tr>
<td>ARB (%)</td>
<td>19.4</td>
<td>0</td>
<td>21.9</td>
<td>1.0</td>
<td>0.110</td>
</tr>
<tr>
<td>Diuretics (%)</td>
<td>94.9</td>
<td>0</td>
<td>78.1</td>
<td>0.6</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Statins (%)</td>
<td>88.8</td>
<td>0</td>
<td>48.2</td>
<td>0.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Antiplatlet (%)</td>
<td>82.5</td>
<td>0</td>
<td>49.8</td>
<td>0.4</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Values are shown in means±SD for continuous values unless stated otherwise; categorical variables are presented as percentages per category.

*Creatinine clearance is calculated with Cockcroft-Gault formula.

ABR, angiotensin II receptor blocker; BMI, body mass index; bpm, beats per minute; CABG, coronary artery bypass grafting; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; EF, ejection fraction; HF, heart failure; LBBB, left bundle branch block; NTproBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; SBP, systolic blood pressure.

5%, p<0.001). After excluding patients with LBBB, QRSd was found to be shorter in Asian compared with white patients with HFPEF (91 vs 94 ms, p=0.006) but longer in Asian compared with white patients with HFREF (102 vs 100 ms, p<0.001).

After multivariable adjustment, there was no longer a significant difference in QRSd among Asians and whites with HFPEF, whereas QRSd was now significantly longer in Asian compared with white patients with HFREF (105 vs 103 ms, p=0.027). Fitted QRSd values derived from the multivariable models are summarised in table 2.

The effect of the addition of each covariate on the relationship between ethnicity and QRSd is shown in figure 2. Covariates that strongly influenced the relationship between ethnicity and QRSd included LBBB, EF, sex, age and height.

Prognostic value of QRSd for HF hospitalisation and mortality in HFPEF and HFREF

During a median follow-up duration of 445 days, 2941 HF hospitalisations (298 Asians, 2643 whites) and 2358 deaths (127 Asians, 2231 whites) occurred.

The association of baseline QRSd (modelled as a continuous variable) with the composite end point of HF hospitalisation or all-cause death was assessed in both Asian and white patients with HFPEF and HFREF in four separate analyses (visualised in figure 3). Among all patients, the multivariable adjusted HR for a 10 ms increase in QRSd was 1.04 (95% CI 1.03 to 1.06, p<0.001). The HR for a 10 ms increase in QRSd was 1.07 (95% CI 0.88 to 1.31, p=0.533) in Asians with HFPEF, 1.02 (95% CI 0.99 to 1.06, p=0.180) in whites with HFPEF, 1.01 (95% CI 0.94 to 1.05, p=0.861) in Asians with HFREF and 1.06 (95% CI 1.04 to 1.07, p<0.001) in whites with HFREF. No significant interactions were found for this composite endpoint. A separate multivariable analysis for HF hospitalisations showed similar results; no interactions were found between ethnicity and QRSd for this event among all patients (pinteraction=0.183) and separately for patients with HFPEF (pinteraction=0.347) and patients with HFREF (pinteraction=0.158). These results indicated that there are no significant differences in the prognostic value of QRSd prolongation between the ethnicities.

Interactions and three-way interactions between the most prominent baseline differences (AF, COPD and diabetes) and QRSd (and ethnicity in case of three-way interactions) in relation with outcome were analysed and found to be non-
Table 2  Values of QRSd by ethnicity before and after multivariable adjustment

<table>
<thead>
<tr>
<th>Patients</th>
<th>QRSd (95% CI)</th>
<th>QRSd (95% CI)</th>
<th>p Value (adjusted)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Asians</td>
<td>Whites</td>
<td>Asians</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>100.8 (99.5 to 102.2)</td>
<td>103.6 (103.2 to 104.0)</td>
<td>104.9 (103.6 to 106.4)</td>
</tr>
<tr>
<td>HFPEF</td>
<td>90.7 (89.0 to 92.6)</td>
<td>95.7 (95.1 to 96.4)</td>
<td>95.3 (92.8 to 98.0)</td>
</tr>
<tr>
<td>HREF</td>
<td>104.1 (102.6 to 105.7)</td>
<td>106.4 (105.9 to 106.9)</td>
<td>108.5 (106.9 to 110.2)</td>
</tr>
<tr>
<td>HFPEF (no LBBB)</td>
<td>90.6 (88.9 to 92.4)</td>
<td>94.0 (93.4 to 94.6)</td>
<td>93.8 (91.3 to 96.4)</td>
</tr>
<tr>
<td>HREF (no LBBB)</td>
<td>102.1 (100.7 to 103.6)</td>
<td>99.5 (99.1 to 99.9)</td>
<td>101.7 (100.1 to 103.4)</td>
</tr>
</tbody>
</table>

Unadjusted and adjusted mean values (with 95% CIs) of QRSd, derived from multivariable linear regression for Asians and whites are shown. The adjusted values represent the QRSd for Asians and whites when all covariates are kept stable in the multivariable linear regression model. QRSd was analysed as 1/QRS as determined by Box-Cox analysis; back-transformed fitted values of 1/QRSd are presented here. The p values represent the p value for ‘ethnicity’ as a predictor of 1/QRS in the multivariable model. The model contained: LBBB (not for the ‘no LBBB’ models), EF (not for the ‘HFPEF’ models), age, sex, ethnicity, height, BMI, DBP, NTproBNP, heart rate, hypertension, diabetes, smoking, history of CAD, history of valve surgery, AF, history of stroke, history of PAD, COPD, NYHA class, creatinine clearance, duration of HF, β-blocker use, ACE inhibitor use, ARB use, diuretic use, statin use and antiplatelet use.

DISCUSSION

These are the first data comparing QRSd and its correlates with prognostic significance between Asian and white patients with HF from parallel prospective population-based cohorts. Ethnicity significantly modified the relationship between EF and QRSd in HF; with a steeper association between QRS prolongation and EF reduction among Asians than whites. While QRSd was generally shorter in Asians than whites in unadjusted comparisons, after multivariable adjustment, there was no longer any ethnic difference in QRSd among patients with HFPEF, whereas among patients with HREF, QRSd was longer in Asians compared with whites. There were no ethnic differences in the association between QRS prolongation and adverse outcomes.

QRS prolongation in patients with HF has been examined among whites, blacks and Hispanics, showing shorter QRSd in blacks than whites with HFREF. No prior studies have evaluated QRSd in Asians versus whites with HF or the association between ethnicity, QRSd and outcomes in HFPEF versus HREF. Extrapolating from findings in the general population, we hypothesised that Asian patients with HF would have narrower QRSd compared with white patients with HF at any given EF. While we indeed found shorter QRSd in Asian patients in unadjusted comparisons, after carefully adjusting for baseline differences between cohorts, we were surprised to find more severe QRS prolongation in Asians compared with whites with HFREF, contrary to our hypothesis. To the extent that EF is a major determinant of QRSd, this is also consistent with the steeper increase in QRSd for a given decline in EF and thus potentially a greater sensitivity to adverse effects of remodelling among Asians compared with whites.

The mechanisms underlying the greater increases in QRSd with decreases in EF in Asians are unclear. One intriguing consideration relates to ethnic differences in what may be considered ‘normal’ QRSd in Asians versus whites. In general population adults without HF, a shorter QRSd has been described in Asians compared with whites. This may relate to intrinsically smaller heart sizes in Asians, as a surrogate of heart size, was directly correlated to QRSd (p<0.001) in the current study. In fact, after adjusting for significant. This indicates that these comorbidities did not change the ethnicity-specific relation of QRSd with outcome.

**Figure 2** The points and lines display the point estimate (β) and 95% CIs of the association of Asian versus white ethnicity with 1/QRS duration (QRSd). The β value represents the difference between Asian and white QRSd. The top estimate displays the unvariable association of ethnicity with 1/QRSd. Subsequently, all covariates that were used in multivariable analysis were cumulatively added to the model (in the order of significance in the final model; most significant covariates first). Variables with a significant relation with 1/QRSd are shown separately in the figure; for each of those models the association of ethnicity with 1/QRSd is shown. The bottom estimate is the result of the full multivariable model; variables with a non-significant relation with 1/QRSd are also included in this model, but not shown separately. BMI, body mass index; CAD, coronary artery disease; EF, ejection fraction; HF, heart failure; LBBB, left bundle branch block; NTproBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association.
height and other covariates (figure 2), the difference in QRSd between Asians and whites with HFPEF was rendered non-significant (table 2), suggesting that differences in body and heart size may indeed account for ethnic differences in QRSd when EF is preserved.

Another consideration relates to what is considered ‘normal’ EF in Asians versus whites. In the general population Multi-Ethnic Study of Atherosclerosis (MESA) cohort, cardiac MRI showed a significantly higher EF of 72% for Chinese than whites (EF 68%).22 Similarly, the EchoNormal study20 showed that ‘normal’ EF is considerably higher in East Asians than in whites (lower reference value for EF 56% vs 50% in 50-year-old men and 57% vs 51% in 50-year-old women). A given low EF measurement in HFREF (eg, EF 30%) may therefore represent a greater EF decline (greater LV eccentric remodelling) in Asians than whites, which may explain the greater extent of QRSd prolongation in Asians than in whites with HFREF. In other words, more severe QRS prolongation in Asians with HFREF may reflect greater scar burden from adverse LV remodelling with a greater reduction in EF from a higher ‘normal’ value in Asians compared with whites.

Interestingly, similar considerations have been applied to explain sex differences in response to device therapy in HFREF, where, using the same QRSd/EF cut-off, women derive greater benefit from device therapy than men.23 This sex difference has been related to known differences in ‘normal’ QRSd and EF between women and men.24

QRS prolongation is known to be a predictor of mortality in HF, as shown in prior studies9 and confirmed in the current. One other study directly compared the prognostic value of QRSd among ethnicities although in a different population (healthy general population); the MESA study25 found no significant interaction between ethnicity (whites, blacks, Hispanics, Chinese) and QRSd in the general population without HF. We, therefore, extend this to the HF population in the current study, showing no modifying effect of ethnicity on the association of QRSd and outcomes.

While our findings are notable, we acknowledge that our observational data from two separate cohorts cannot provide conclusive evidence for different QRSd cut-offs for Asians and whites and cannot be extrapolated to response to treatment such as cardiac resynchronisation therapy. We had limited statistical power to assess outcomes in the HFPEF subgroups and were unable to assess the ethnicity-specific relationships of QRSd with outcome between the HF types (ie, test for three-way interactions among ethnicity, QRSd and HF type).

Figure 3  Cox regression survival estimates (hazard ratios) are displayed for Asian (in blue, left panel) and white (in red, right panel) patients with heart failure (HF), using 120 ms as the reference value. The top two plots show the relation of QRS duration (QRSd) with outcome for patients with HF with preserved ejection fraction (HFPEF), the bottom two for patients with HF with reduced ejection fraction (HFREF). The outcome is HF hospitalisation or all-cause death. The plotted estimates are derived from univariable analysis. The shaded areas represent the 50% CI (darkest area) and the 95% CI (lighter area). No significant interaction between QRSd and ethnicity was found for outcome (no significant differences between the slopes of the lines for Asians and whites).
The divergence of the direction of the association of ethnicity with QRSd between patients with HFpEF and patients with HFREF renders a systematic measurement error between SwedeHF and SHOP highly unlikely.

While SwedeHF and SHOP are large universal real-life registries in which EF was systematically collected for all patients, more detailed aspects from echocardiography such as LV dimensions or mass unfortunately were unavailable in SwedeHF. Therefore, we could not perform a direct comparison of the relationship between QRSd and LV size or mass in the combined cohort and it remains possible that differences in heart size mediated the observed differences in QRSd.

Data collection occurred through separate although similar protocols in SwedeHF and SHOP; thus, differences in data collection are unavoidable. However the majority of the merged data were standard variables in HF that are uniformly assessed globally and data collection periods of the cohorts were deliberately matched. While we cannot have perfect matching on all fields, ours is the only combined database of population-based HF from European and Asian countries. Also, the median follow-up of 445 days may not be long enough to reveal prognostic differences. Results may therefore be considered hypothesis-generating and deserve further study in contemporaneous parallel prospective studies using identical protocols in different countries.

We carefully adjusted our cross-sectional and survival analyses for all available baseline variables; however, residual confounding by unmeasured characteristics cannot be excluded. Separate analyses for patients with LBBB alone were not feasible due to low patient numbers in those groups.

CONCLUSIONS

These first data comparing QRSd between Asian and white patients with HF from parallel prospective population-based cohorts showed that ethnicity significantly modified the relationship between EF and QRSd in HF, with a steeper association between QRS prolongation and EF reduction among Asians compared with whites. Further studies are needed to determine whether ethnicity-specific QRSd cut-offs for clinical decision-making regarding device therapy in HF should be considered.

Author affiliations
1ICIN-Netherlands Heart Institute, Utrecht, The Netherlands
2Laboratory of Experimental Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands
3Department of Clinical Science and Education, Karolinska Institutet, Stockholm, Sweden
4Department of Cardiology, Linköping University, Linköping, Sweden
5Department of Medical and Health Sciences, Linköping University, Linköping, Sweden
6National Heart Centre, Singhealth, Singapore, Singapore
7Department of Cardiology, Tan Tock Seng Hospital, Singapore, Singapore
8Department of Cardiology, Khoo Teck Puat Hospital, Singapore, Singapore
9Department of Medicine/Cardiology, Singapore General Hospital, Singapore, Singapore
10Duke-NUS, Singapore, Singapore
11Department of Cardiology, Changi General Hospital, Singapore, Singapore
12Yong Loo Lin School of Medicine, National University, Singapore, Singapore
13Cardiac Department, National University Health System, Singapore, Singapore
14Cardiovascular Research Institute, National University, Singapore, Singapore
15Christchurch Heart Institute, University of Otago, Christchurch, New Zealand
16Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
17Department of Cardiology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

Contributors DS, DPSY, HYO, FJ, GKT, LIHL, AMR, UD, LaHL and CSPL provided substantial contributions to data acquisition. LB and CMG performed data analysis and DPVdK, LaHL and CSPL assisted in interpreting the results. The manuscript was drafted by CMG, LS, LaHL and LB. DS, DPSY, HYO, FJ, GKT, LIHL, AMR, UD and DPVdK critically revised the manuscript for important intellectual content. All authors provided approval to publish the manuscript in its current form. All authors have agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. CSPL is guarantor of this article.

Funding This work was supported by grants to Lars Lund’s Institution from Swedish Research Council (grant 2013-23897-104640-23); Swedish Heart Lung Foundation (grants 20100419, 20120321); Stockholm County Council (grants 20110120, 20140220); Swedish Society of Medicine (grant 174111) and Boston Scientific. This work was additionally supported by a Strategic grant from the Royal Netherlands Academy of Arts and Sciences to the Interuniversity Cardiology Institute of the Netherlands, ICIN to DPVdK; National University Singapore Startup grant to DPVdK, Singapore National Medical Research Council Grant to AMR, DPVdK and CSPL and the ATTRAICT, SPF 2014/003 grant BMRC to CSPL, DPVdK and AMR. CSPL is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore and has received research support from Boston Scientific, Medtronic and Vifor Pharma.

Competing interests None declared.

Ethics approval Multisite IRB Singapore and multisite Ethics Committee in Sweden.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES
Heart failure and cardiomyopathies


